+357 96 030922
info@marketpublishers.com

Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutic (Intravenous Immunoglobulin (IVIG)), By Type (AIDP), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

https://marketpublishers.com/r/GF10057CF596EN.html
Date: January 2025
Pages: 130
Price: US$ 5,950.00 (Single User License)
ID: GF10057CF596EN

Abstracts

This report can be delivered to the clients within 3 Business Days

Guillain-Barre Syndrome Market Growth & Trends

The global guillain-Barre syndrome market size is anticipated t%li%reach USD 1.03 billion by 2030 and is expected t%li%expand at a CAGR of 6.10% during the forecast period, according t%li%a new report by Grand View Research, Inc. The increasing prevalence of Guillain-Barr? Syndrome (GBS), a rare but serious autoimmune disorder affecting the peripheral nervous system, is driving growth opportunities in the healthcare sector. Businesses can capitalize on this market expansion through advancements in treatment modalities, diagnostic tools, and patient care solutions. The demand for effective therapies such as Intravenous Immunoglobulin (IVIG) and Plasma Exchange is rising, necessitating improved access t%li%these treatments via hospital and retail pharmacies.

GBS presents in multiple variants, each requiring specialized medical approaches. Acute Inflammatory Demyelinating Polyneuropathy (AIDP) is the most common form in North America and Europe, characterized by progressive muscle weakness and sensory disturbances. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), a related but chronic condition, necessitates long-term management strategies, creating sustained demand for therapeutic interventions. Miller Fisher Syndrome (MFS), a rarer variant, primarily affects eye movement and coordination, necessitating targeted neurological treatments. Acute Motor Axonal Neuropathy (AMAN), more prevalent in Asia and Latin America, underscores the need for region-specific diagnostic and therapeutic developments.

Recent outbreaks of GBS, potentially linked t%li%viral infections such as Zika and other emerging pathogens, have intensified market interest. A surge in cases drives the need for enhanced surveillance, early diagnosis, and timely therapeutic intervention, boosting investment in healthcare infrastructure. Governments and pharmaceutical companies are increasing research efforts t%li%develop new treatment options and improve existing protocols. The outbreak-driven demand for IVIG and Plasma Exchange, primary treatments for GBS, has put pressure on global plasma supply chains, encouraging innovation in alternative therapies.

The COVID-19 pandemic has further impacted the GBS market, as studies have indicated a potential association between SARS-CoV-2 infection and an increased risk of GBS. The surge in COVID-19 cases led t%li%a rise in reported GBS diagnoses, driving higher demand for IVIG and Plasma Exchange treatments. In addition, pandemic-related disruptions in healthcare supply chains have affected the availability of essential therapies, necessitating strategic adjustments in pharmaceutical production and distribution. Increased awareness and research int%li%post-viral neurological complications have als%li%propelled investment int%li%GBS diagnostics and treatment innovations.

Treatment delivery methods are evolving, with both parenteral and oral options under exploration. While IVIG remains the gold standard for acute cases, research int%li%oral immunomodulatory treatments is gaining momentum, potentially offering more accessible long-term management solutions for CIDP patients. Pharmacies play a crucial role in GBS treatment distribution. Hospital pharmacies dominate the market due t%li%the need for inpatient care and close monitoring during IVIG or Plasma Exchange therapy. However, retail pharmacies are expanding their role in CIDP management, providing patients with convenient access t%li%maintenance therapies and supportive medications.

With increasing awareness, evolving treatment approaches, and growing pharmaceutical investment, the GBS market is poised for significant growth. Innovations in both acute and chronic care solutions will continue t%li%shape the landscape, creating new opportunities for businesses in healthcare, therapeutics.

Guillain-Barre Syndrome Market Report Highlights

+357 96 030922
info@marketpublishers.com

Intravenous Immunoglobulin (IVIG) dominated the Guillain-Barr? Syndrome (GBS) treatment market in 2024. This dominance is driven by IVIG's proven efficacy in modulating the immune response, reducing disease progression, and improving recovery rates, making it the preferred first-line treatment for GBS.

Acute Inflammatory Demyelinating Polyneuropathy (AIDP) held the largest market share among GBS subtypes in 2024. As the most common form of GBS, particularly in North America and Europe, AIDP's prevalence significantly influences the demand for effective therapeutic options, further strengthening its market dominance.

Parenteral led the GBS treatment market in 2024. Given the critical nature of the disease, IV-administered treatments such as IVIG and plasma exchange ensure rapid and effective therapeutic action, enhancing patient outcomes in both acute and severe cases.

Hospital pharmacies remained the dominant distribution channel in 2024. Due t%li%the need for immediate medical intervention and specialized care, hospital pharmacies play a crucial role in ensuring the availability and administration of GBS treatments, particularly in acute care settings.

North America led the GBS treatment market, attributed t%li%factors such as a well-established healthcare infrastructure, high awareness of neurological disorders, and the availability of advanced treatment options. The region's strong focus on research and innovation further supports market growth.

+357 96 030922
info@marketpublishers.com

Contents

8.2.2. U.S.
8.2.2.1. U.S. Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.3. Canada
8.2.3.1. Canada Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.4. Mexico
8.2.4.1. Mexico Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3. Europe
8.3.1. Europe Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.2. UK
8.3.2.1. UK Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.3. Germany
8.3.3.1. Germany Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.4. France
8.3.4.1. France Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.5. Italy
8.3.5.1. Italy Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.6. Spain
8.3.6.1. Spain Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.7. Denmark
8.3.7.1. Denmark Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.8. Norway
8.3.8.1. Norway Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.9. Sweden
8.3.9.1. Sweden Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

CHAPTER 9. COMPETITIVE LANDSCAPE

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutic (Intravenous Immunoglobulin (IVIG)), By Type (AIDP), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Product link: https://marketpublishers.com/r/GF10057CF596EN.html

Price: US$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GF10057CF596EN.html